Axsome Therapeutics' Q3 2024 earnings report shows a revenue beat with $104.8m. See why I think selling AXSM stock on any ...
Axsome Therapeutics surpassed revenue expectations in Q3, driven by strong sales from its key products.
Investors are all-in on Axsome's potential, especially with FDA action dates looming. AXS-07, the migraine fighter, could get the green light by the beginning of 2025, and Phase 3 trial results for ...
Pfizer and Lilly’s telehealth prescribing platforms draw Senate scrutiny for ‘potential fraud’
Eli Lilly launched LillyDirect to help patients with obesity, diabetes and migraine navigate a complex healthcare system, a ...
According to a new comprehensive report from The Insight Partners, The botulinum toxin market is expected to reach a value of US$ 19.03 billion by 2031 from US$ 7.38 billion in 2023 at a CAGR of 12.6% ...
In the 630 Battle of al-Qadisiyah, the Arab army emerged victorious and continued its march into Persia, contributing to the spread of Islam beyond West Asia.
Amid fears of an "extremely high level of violent protests," the Brampton Triveni Mandir and Community Centre has cancelled a Life Certificate Event.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback